关键词:  , 癌,非小细胞肺, 抗肿瘤联合化疗方案, 吉西他滨, 顺铂, 中位无复发
生存时间, 无病生存率

Abstract: Objective  To observe the short-term efficacy of GP regimen in adjuvant chemotherapy in patients with non-small-cell lung cancer，and to study t
he factors influencing efficacy and analyze the adverse reactions.
Methods  Clinical data of 68 NSCLC patients received postoperative adjuvant chemotherapy of GP regimen was  retrospectively analyzed.Kaplan-Meier method was used to draw the disease-free survival curve.Log-rank time series analysis was used between different subgroups;C
OX proportional hazards model was used for the univariate and multivariate analyses.
Results  Of all the 68 cases，the median recurrence-free survival time was 33.7 months，56 cases were followed up more than one year，and one year disease-free survival rate was 83.9%;25 cases were followed up more than two years，and
two-year disease-free survival was 72.0%.Univariate analysis suggested that clinical stage(P<0.05)，pathological type(P<0.05),degree of differentiation(P<0.05) significantly influenced the short-term efficacy. Multivariate analysis suggested that clinical stage(P<0.05),degree of differentiation(P<0.05) were thei
ndependent factors of the short-term efficacy.The major adverse reactions were stage 3 to 4 myelo-suppression including neutropenia（33.9%），granulocytopenia（20.6%），anemia（4.4%），and thrombocytopenia（4.4%），and  stage 3 to 4 nausea and vomiting(10.3%).
Conclusion The GP regimen is feasible,well-tolerated with a high disease control rate in one or two years in the adjuvant chemotherapy;clinical stage
and degree of differentiation are the independent factors of the short-term efficacy.

Key words: cancer,non-small cell lung, antineoplastic combined chemotherapy protocols, gemcitabine, cisplatin, median recurrence-freesurvival time, disease-free survival rate